


RECEIVED

JAN 31 2000

GENENTECH, INC.
LEGAL DEPT.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

TS/LS

DK

APPLICATION NO.	PATENT NO.	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	------------	----------------------	---------------------

09/314,295

01/17/99

LEE

J

01/17/99

EXAMINER

MURPHY, J

ART UNIT

PAPER NUMBER

14/14

6

DATE MAILED:

01/17/99

TIMOTHY R SCHWARTZ PH.D

GENENTECH, INC.

1 DNA WAY

SOUTH SAN FRANCISCO CA 94020-4000

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

CALENDARED/~~24~~²⁵

Notice to Comply

24 FEB 00

DUE DATE



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

09313299

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
ART UNIT	PAPER NUMBER
	6
DATE MAILED:	


Please find below a communication from the EXAMINER in charge of this application


The communication filed on **11/22/99** is not fully responsive to the communication mailed **10/29/99** for the reason(s) set forth on the attached Notice to Comply With the Sequence Rules or CRF Diskette Problem Report.

Since the response appears to be **bona fide**, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is given **ONE (1) MONTH** from the mailing date of this notice within which to supply the omission or correction in order to avoid abandonment. **EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).**

Any inquiry concerning this communication should be directed to Examiner **Joseph F. Murphy**, Art Unit **1644**, whose telephone number is **703-305-7245**.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.


Joseph F. Murphy, Ph.D.
Patent Examiner
Art Unit 1644
December 30, 1999



PREMA MERTZ
PRIMARY EXAMINER



GAU 1644WD
PMP SEQ

Patent Docket No. P0963R1D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of James Lee et al. Serial No.: 09/313,299 Filed: May 17, 1999 For: VEGF - RELATED PROTEIN	Examiner: J. Murphy Art Unit: 1644 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on March 13, 2000  Tara E. Faenza
--	--

TRANSMITTAL LETTER

BOX SEQUENCE
Assistant Commissioner for Patents
Washington, DC 20231

MAR 23 2000
TECH CENTER 1600/2900

Sir:


Enclosed for filing in the above-identified patent application, please find:

1. Response to Notice to Comply with the Requirement for Patent Application Containing Sequence Disclosures;
2. Copy of Notice to Comply with the Requirement for Patent Application Containing Sequence Disclosures;
3. Sequence Listing and computer-readable diskette;
4. Petition for One Month Extension of Time.
5. A return postage-prepaid postcard.

The Commissioner is authorized to charge any additional fees due in connection with the filing of these documents to our Deposit Account No. 07-0630 (our Docket P0963R1D1). A duplicate copy of this transmittal is enclosed.

Respectfully submitted,
GENENTECH, INC.

Date: March 13, 2000

By: 
Timothy R. Schwartz, Ph.D.
Reg. No. 32,171


1 DNA Way
South San Francisco, CA 94080-4990
Phone: (650) 225-7467
Fax: (650) 952-9881

MAR 21 2000
TECH CENTER 1600/2900



Patent Docket No. P0963R1D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of James Lee et al. Serial No.: 09/313,299 Filed: May 17, 1999 For: VEGF - RELATED PROTEIN	Examiner: J. Murphy Art Unit: 1644 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on March 13, 2000  Tara E. Faenza
--	---

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATION CONTAINING SEQUENCE DISCLOSURES**

BOX SEQUENCE

Assistant Commissioner for Patents
Washington, DC 20231

Sir:


In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed January 24, 2000, transmitted herewith are the following documents:

1. Copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
2. Sequence Listing and computer-readable diskette;

The Commissioner is authorized to charge any additional fees due in connection with the filing of these documents to our Deposit Account No. 07-0630 (our Docket P0963R1D1). A duplicate copy of this transmittal is enclosed.

Respectfully submitted,
GENENTECH, INC.

Date: March 13, 2000

By: 
Timothy R. Schwartz, Ph.D.
Reg. No. 32,171

1 DNA Way
South San Francisco, CA 94080-4990
Phone: (650) 225-7467
Fax: (650) 952-9881

#72020


Murphy

RAW SEQUENCE LISTING

ERROR REPORT



BIOTECHNOLOGY
SYSTEMS
BRANCH



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number:

09/313,299A

Art Unit / Team No. :

1646

Date Processed by STIC:

12/10/99

THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.

PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,

2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY

THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.

IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:

MARK SPENCER 703-308-4212

Raw Sequence Listing Error Summary

ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER:

09/313,299A

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 ☐ **Wrapped Nucleics** The number/text at the end of each line "wrapped" down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 2 ☐ **Wrapped Aminos** The amino acid number/text at the end of each line "wrapped " down to the next line.
This may occur if your file was retrieved in a word processor after creating it.
Please adjust your right margin to .3, as this will prevent "wrapping".
- 3 ☐ **Incorrect Line Length** The rules require that a line not exceed 72 characters in length. This includes spaces.
- 4 ☐ **Misaligned Amino Acid Numbering** The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
- 5 ☐ **Non-ASCII** This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
- 6 ☐ **Variable Length** Sequence(s) ☐ contain n's or Xaa's which represented more than one residue.
As per the rules, each n or Xaa can only represent a single residue.
Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.
- 7 ☐ **PatentIn ver. 2.0 "bug"** A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) ☐. Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence.
- 8 ☐ **Skipped Sequences (OLD RULES)** Sequence(s) ☐ missing. If intentional, please use the following format for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO:X:
(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
This sequence is intentionally skipped

Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
- 9 ☐ **Skipped Sequences (NEW RULES)** Sequence(s) ☐ missing. If intentional, please use the following format for each skipped sequence.
<210> sequence id number
<400> sequence id number
000
- 10 ☐ **Use of n's or Xaa's (NEW RULES)** Use of n's and/or Xaa's have been detected in the Sequence Listing.
Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 11 ☐ **Use of <213>Organism (NEW RULES)** Sequence(s) ☐ are missing this mandatory field or its response.
- 12 ☒ **Use of <220>Feature (NEW RULES)** Sequence(s) ☐ are missing the <220>Feature and associated headings.
Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"
Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
- 13 ☐ **PatentIn ver. 2.0 "bug"** Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
Instead, please use "File Manager" or any other means to copy file to floppy disk.



Application No.: 09312299

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE